Cell line · CVCL_0235
Caki-2
Cancer cell line, Homo sapiens. Papillary renal cell carcinoma. Cellosaurus records it as misclassified. 47 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Caki-2. Cell lines, record CVCL_0235. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0235
On this page
Cell line
As Cellosaurus gives it.
- Name
- Caki-2
- Accession
- CVCL_0235
- RRID
- RRID:CVCL_0235
- Synonyms
- CAKI-2, CaKi-2, caki-2, CAKI 2, Caki 2, Caki2, CAKI2
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 69Y
- Category
- Cancer cell line
- Diseases
- Papillary renal cell carcinoma (NCIt C6975); Papillary renal cell carcinoma (ORDO Orphanet_319298)
- Derived from
- Kidney (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Misclassified | Originally thought to be a clear cell renal cell carcinoma but shown to be from a papillary renal cell carcinoma (PubMed=17409424; PubMed=27993170). |
Source Cellosaurus
Papers47
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Inhibition of PLK1 helps to restrict c-Met-induced growth and therapeutic resistance of renal cancer cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting and dissociating HIF2α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. | Commun Med (Lond) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Prolonged exposure to axitinib alters the molecular profile of Caki-2 renal cell carcinoma cells. | Mol Clin Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the IL34-CSF1R axis improves metastatic renal cell carcinoma therapy outcome via immune-vascular crosstalk regulation. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD8+ T cell-derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ankrd1 Promotes Lamellipodia Formation and Cell Motility via Interaction with Talin-1 in Clear Cell Renal Cell Carcinoma. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 47
See all 47 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | Caki-2 DNMT3A KO | CVCL_E3VW | Has a recorded problem |
Source Cell lines
Cell banks10
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-47 | ATCC | |
| BCRJ | 0408 | BCRJ | |
| CLS | 300140 | CLS | |
| CancerTools | 161904 | CancerTools | |
| DSMZ | ACC-54 | DSMZ | |
| ECACC | 93120819 | ECACC | |
| Hysigen | TCH-C592 | Hysigen | |
| ICLC | HTL95029 | ICLC | |
| IZSLER | BS TCL 8 | Cellosaurus | |
| KCLB | 30047 | KCLB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0235
GET https://conductscience.org/api/cell-lines/v1/CVCL_0235/papers?page=2